Ligand Pharmaceuticals Inc (LGND) Institutional Ownership

Ownership Summary

Ligand Pharmaceuticals Inc (NASDAQ:LGND) currently has 9 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• Institutional ownership in Ligand Pharmaceuticals edged down to 2.6% in December 2025, compared to 175.5% in September 2025.
• The company experienced a -26.17% quarterly change in institutional shares held, alongside a decrease of 96.47% in total owners annually.
• During the quarter, 4 institutions bought more Ligand Pharmaceuticals shares, 3 sold shares, and 2 of the 9 total investors held their position steady.
• The total number of shares held by institutions in Ligand Pharmaceuticals decreased to 547.10K as of December 2025, a net change of down by 193.97K shares quarter on quarter, and down 17.65Mn shares year over year.
• CONGRESS ASSET MANAGEMENT CO continues to be the largest institutional holder of Ligand Pharmaceuticals as of December 31, 2025, with a position of 480.06K shares, representing 2.33% of the company's outstanding stock.
• Among the most significant buyers of Ligand Pharmaceuticals during December 2025 were PARK AVENUE SECURITIES LLC (1.40K), GAMMA Investing LLC (52), MassMutual Private Wealth & Trust, FSB (6), Park Place Capital Corp (4).
• Leading sellers of Ligand Pharmaceuticals stock in December 2025 included CONGRESS ASSET MANAGEMENT CO (187.25K), NORDEA INVESTMENT MANAGEMENT AB (7.28K), SG Americas Securities, LLC (905).
• The top 9 institutional holders of Ligand Pharmaceuticals for the quarter ending December 2025 included CONGRESS ASSET MANAGEMENT CO (480.06K), NORDEA INVESTMENT MANAGEMENT AB (53.73K), SG Americas Securities, LLC (10.82K), PARK AVENUE SECURITIES LLC (1.40K), GAMMA Investing LLC (627), Versant Capital Management, Inc (256), MassMutual Private Wealth & Trust, FSB (150), Retirement Wealth Solutions LLC (57), Park Place Capital Corp (4).